Citalopram and Amphetamine Combination: Serotonin Syndrome and Cardiovascular Risks

Concurrent use of citalopram (SSRI) and amphetamine (stimulant) is contraindicated due to synergistic serotonergic and cardiovascular toxicity.

Serotonin Syndrome (Life-Threatening)

  • Mechanism: SSRI blocks serotonin reuptake; amphetamine releases serotonin → excessive synaptic serotonin.
  • Hunter Criteria (diagnosis): Spontaneous clonus, inducible/ocular clonus + agitation/diaphoresis, tremor + hyperreflexia, hypertonia + fever + ocular/inducible clonus.
  • Symptoms: Agitation, confusion, hyperreflexia, clonus, rigidity, hyperthermia (>38.5°C), tachycardia, hypertension, diarrhoea, mydriasis, seizures.
  • Treatment: Discontinue serotonergic agents, supportive cooling, benzodiazepines, cyproheptadine (5-HT₂A antagonist), ICU monitoring.

Cardiovascular Risks

  • Citalopram: Dose-dependent QT prolongation (max 40 mg/day; 20 mg if >60 yr or CYP2C19 poor metabolizer).
  • Amphetamine: ↑ Heart rate, BP, catecholamines → arrhythmia, MI, stroke risk.
  • Combination: Additive QT prolongation + catecholamine surge → torsades de pointes, hypertensive crisis, stroke.

Other Risks

  • Seizure threshold lowering (both agents)
  • Hyponatraemia (SSRI + stimulant-induced SIADH/exercise)
  • Psychiatric destabilization (mania, psychosis)

Clinical Imperative

Do not co-prescribe. If ADHD and depression coexist, consider non-stimulant ADHD options (atomoxetine, guanfacine XR, bupropion) or alternative antidepressants with lower serotonergic burden, under specialist supervision. Washout periods apply when switching.

Drug Addiction - Related Articles